Overview
CLOVER BIO-B (2197)
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland Ch...
- Open
- 1.660
- High
- 1.675
- Low
- 1.590
- Prev. Close
- 1.665
- Volume
- 2.15M
- Turnover
- 3.52M
- Avg Price
- 1.633
- Bid/Ask Ratio
- 37.84%
- Amplitude
- 5.11%
- 52wk High
- 3.200
- Volume Ratio
- 0.32
- Turnover Ratio
- 0.17%
- 52wk Low
- 1.110
- HK Mkt Cap
- 2.15B
- Market CapHKD
- 2.15B
- P/ETTM
- 2.19
- P/EDynamic
- 0.98
- P/EStatic
- --
- EPSTTM
- 0.755
- EPSDynamic
- 1.69
- EPSStatic
- --
- BVPS
- -0.71
- P/B
- --
- HK Shares
- 1.30B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.30B
- Min lot size
- 500
- Currency
- HKD
CLOVER BIO-B Analyst Rating
View moreForecast & Rating
Jan 9, 2024- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Clover Biopharmaceuticals rallied in the afternoon session, climbing from a session low of 1.66 HKD to an intraday high of 1.79 HKD, before closing at 1.77 HKD, up 4.1% from the previous close of 1.70 HKD, with an intraday range of 8.2%. The move was catalyzed by news of a cap-limited settlement with Gavi to terminate arbitration, alleviating a US$224 million exposure. Year-to-date, the stock is down 25.3%, trading 44.7% below its 52-week high of 3.2 HKD. While the current price sits above the 20-day moving average (1.66 HKD), it remains below the 60-day moving average (2.37 HKD). Q4 revenue plunged 99.5% YoY to HK$140 thousand, though net loss narrowed 86.6%, with EPS improving to -0.046 HKD. Net profit margin, however, remains deeply negative, underscoring the distance to a sustainable recovery.
News
Weekly Review · Weekly Recap | CLOVER BIO-B +17.25%, outperforming the HSI by ~20pts
Market Movers · Clover Biopharmaceuticals climbs 13% in Hong Kong trading
Market Movers · Clover Biopharmaceuticals surges 12% in Hong Kong trading
Weekly Review · Weekly Recap | CLOVER BIO-B +5.88%, consensus target above spot
Market Movers · Clover Biopharmaceuticals drops 6%
Market Movers · Clover Biopharmaceuticals climbs 7%
